Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) are major global health challenges with high morbimortality. The EP PerMed projects UNMASK and OPTIMA aim to improve understanding of the molecular mechanisms of these diseases using omics-based approaches to support personalised prevention and innovative strategies in African and European populations. To maximise societal benefit, translation of findings into clinical practice and prevention must be strengthened. This hybrid networking event, organised in Seville (Spain) and online, will gather researchers, clinicians, omics experts, patient representatives and policymakers to accelerate the transfer of EP PerMed results into healthcare solutions. Objectives include integrating omics and biomarker findings into clinical frameworks, overcoming translational barriers, promoting equitable personalised approaches, and building a sustainable collaborative network.

The networking event, that will take place in Seville on the 1st and 2nd of June 2026, aims to accelerate the translation of omics-based discoveries into personalised prevention and care for metabolic disorders, with a focus on MASLD and T2DM. It is collaboratively organised by the ERA/EP PerMed projects UNMASK and OPTIMA, which generate complementary biomarker and risk-stratification knowledge across European and African populations. The main objective is to integrate project results into actionable clinical and regulatory frameworks for personalised medicine implementation. Key translational stakeholders involved include clinicians (hepatologists and endocrinologists), omics experts, HTA specialists, regulators, and patient advocacy organisations such as the European Liver Patients’ Association (ELPA). The event also engages international stakeholders outside ERA/EP PerMed, including African research cohorts from the Wits Health Consortium in South Africa. By fostering cross-disease and cross-continent collaboration, the event seeks to overcome regulatory, equity, and implementation barriers. Ultimately, it will build a sustainable network that bridges research, healthcare systems, and patients to improve prevention and treatment of metabolic diseases.